This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Getty Images milla1cf Tue, 02/06/2024 - 20:36 February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial ( NCT05883631 ), a study formally launched in late October 2023. AFib is the most common heart rhythm disorder, affecting more than 30 million patients worldwide.
The AFib pulsed field ablation treatment era officially began in the US last week, following the FDA approval of Medtronic’s PulseSelect Pulsed Field Ablation System for the treatment of both paroxysmal and persistent atrial fibrillation. PFA systems use electroporation (short electrical pulses) to achieve pulmonary vein isolation.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
Compared with a sham procedure, pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation (AFib) burden at six months, according to results from the SHAM-PVI trial presented at ESC Congress 2024 in London and simultaneously published in JAMA.
milla1cf Thu, 03/28/2024 - 07:28 March 28, 2024 — Biosense Webster, Inc., Based on the results from the admIRE clinical trial, we are confident that this innovation has the promise to deliver significant value and differentiated capabilities, and become an important tool for the treatment of AFib." In the U.S.,
Image courtesy: Getty Images christine.book Wed, 07/24/2024 - 09:00 July 24, 2024 — Volta Medical , a health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists, has announced a Joint Development Agreement with GE HealthCare.
Performing additional catheter ablations targeting diseased myocardium along with the standard approach of pulmonary vein isolation (PVI) to treat persistent atrial fibrillation (AFib) did not reduce the recurrence of AFib at one year, based on findings from the SUPPRESS-AF trial presented at ESC Congress 2024 in London.
milla1cf Fri, 02/02/2024 - 17:02 February 2, 2024 — Biosense Webster, Inc. , The results support the use of workflows to reduce radiation exposure during catheter ablation for the treatment of paroxysmal atrial fibrillation (AFib) while maintaining safety, efficacy, and long-term patient outcomes comparable to traditional procedures.1
The pipeline of algorithms likely to clear regulatory hurdles and enter the cardiac market over the next 12-18 months include those for Pulmonary Hypertension, Cardiac Amyloidosis, Diastolic dysfunction, and Hyperkalaemia. Fertile Partnerships Ongoing research partnerships have driven much of recent developments seen in the market.
Retrieved July 2, 2022, from [link] == MY Comment , by K EN G RAUER, MD ( 2/4 /2024 ): == Today's case by Dr. Meyers provides insight with regard to sequential evolution of serial ECGs during the course of cardiac contusion. Other Arrhythmias ( PACs, PVCs, AFib, Bradycardia and AV conduction disorders — potentially lethal VT/VFib ).
NOTE: For more on ECG recognition of RVH and/or pulmonary hypertension ( re the qR pattern in lead V1 ) — See ECG Blog #234 and Blog #248. A DDENDUM ( 4/14/2024 ): Based on some questions that have arisen regarding the PR intervals in ECG #1 and ECG #2 — I've added Figure-7 , that I hope will clarify my discussion.
Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases.
Smith : This is classic for pulmonary embolism (PE). Acute pulmonary embolism was confirmed on CT angiogram: The patient did well. See our other acute right heart strain / pulmonary embolism cases: A man in his 50s with shortness of breath Another deadly triage ECG missed, and the waiting patient leaves before being seen.
New science presented at AHA 2024 and simultaneously published in JACC: Advances provide insights on emerging topics such as the use of artificial intelligence (AI)-enabled left atrial (LA) volumetry in coronary artery calcium (CAC) scans to predict atrial fibrillation (AFib); the role of treating hospitals in facilitating cardiac rehabilitation (CR); (..)
tim.hodson Wed, 10/30/2024 - 13:42 Oct. tim.hodson Wed, 10/30/2024 - 13:42 Oct. With this approval, Medtronic now offers two PFA technologies available for patients with Afib. With a short learning curve for experienced physicians, the possibilities are boundless for the treatment of Afib," said Vivek Reddy, M.D.,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content